NewLink Genetics Corporation (NASDAQ:NLNK) Files An 8-K Other EventsItem 8.01.Other Events.
On July 10, 2017, NewLink Genetics Corporation, a Delaware corporation, or the Company, issued a press release titled "NewLink Genetics Receives Notice of Allowance from USPTO Covering Indoximod Salts and Prodrugs."
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Section9 – Financial Statements and Exhibits
Item 9.01.FinancialStatements and Exhibits.
(d) Exhibits.
|
ExhibitNumber |
Description |
|
99.1 |
Press Release, dated July 10, 2017, entitled “NewLink Genetics Receives Notice of Allowance from USPTO Covering Indoximod Salts and Prodrugs” |
NEWLINK GENETICS CORP ExhibitEX-99.1 2 nlnk-20170710x8kxex991.htm PRESS RELEASE Exhibit Exhibit 99.1FOR IMMEDIATE RELEASENewLink Genetics Receives Notice of Allowance from USPTO Covering Indoximod Salts and ProdrugsAMES,…To view the full exhibit click here
About NewLink Genetics Corporation (NASDAQ:NLNK)
NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system. Algenpantucel-L is its clinically advanced product candidate for patients with pancreatic cancer. Its additional HyperAcute cellular HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma. It has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system’s tolerance to cancer.